Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEPH 
Nephros Inc (NEPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: NEPH (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 98.24% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.48M USD | Price to earnings Ratio 41.32 | 1Y Target Price 7 |
Price to earnings Ratio 41.32 | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 1.47 | 52 Weeks Range 1.39 - 6.42 | Updated Date 12/4/2025 |
52 Weeks Range 1.39 - 6.42 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.015 | Actual 0.03 |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 6.59% |
Management Effectiveness
Return on Assets (TTM) 7.64% | Return on Equity (TTM) 16.29% |
Valuation
Trailing PE 41.32 | Forward PE - | Enterprise Value 53367088 | Price to Sales(TTM) 3.43 |
Enterprise Value 53367088 | Price to Sales(TTM) 3.43 | ||
Enterprise Value to Revenue 2.98 | Enterprise Value to EBITDA 32.32 | Shares Outstanding 10626683 | Shares Floating 8659471 |
Shares Outstanding 10626683 | Shares Floating 8659471 | ||
Percent Insiders 11.31 | Percent Institutions 47.19 |
Upturn AI SWOT
Nephros Inc
Company Overview
History and Background
Nephros, Inc. was founded in 1997. Initially focused on developing and commercializing medical devices related to dialysis, the company has expanded its offerings to include ultrafiltration and fluid management technologies for various applications, including infection control and biopharmaceutical manufacturing. Key milestones include FDA clearances for its hemodiafiltration system and its commercial expansion into diverse markets.
Core Business Areas
- Medical Device Segment: Development, manufacturing, and sale of proprietary ultrafilters and related products for use in hemodialysis and hemodiafiltration, primarily for treating patients with chronic kidney disease. Includes dialyzers and bloodlines.
- Water Purification Segment: Development, manufacturing, and sale of ultrafilters for water purification and infection control applications. Primarily focused on providing filters for hospitals and other healthcare facilities to reduce the risk of waterborne pathogens.
- Biopharmaceutical Segment: Development, manufacturing, and sale of ultrafilters for biopharmaceutical companies to purify liquids and filtration to create drug products.
Leadership and Structure
Nephros Inc.'s leadership team typically consists of a CEO, CFO, and other key executives overseeing various departments such as R&D, sales, and marketing. The organizational structure is generally hierarchical, with functional departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- HDF Assist Module: A hemodiafiltration (HDF) system that integrates with existing dialysis machines. Market share is small, however, as larger dialysis providers like Fresenius and DaVita make their own equipment. Competitors include Fresenius Medical Care (FMS), Baxter International (BAX), and Asahi Kasei.
- Nephros S/O Ultrafilters: Used in hospitals for infection control to prevent waterborne pathogens. Competitors include Pall Corporation (acquired by Danaher Corporation), and Mar Cor Purification (part of Cantel Medical).
Market Dynamics
Industry Overview
The market includes dialysis equipment and services, water purification for medical applications, and filtration systems for biopharmaceutical manufacturing. Key trends include growing prevalence of chronic kidney disease, increasing demand for infection control solutions in hospitals, and growth in the biopharmaceutical industry.
Positioning
Nephros occupies a niche market focused on ultrafiltration technology. Its competitive advantage lies in its proprietary filter designs and its focus on specific applications like HDF and infection control.
Total Addressable Market (TAM)
The TAM for dialysis equipment, water purification, and biopharmaceutical filtration is estimated to be in the billions of USD. Nephros is positioned to capture a portion of this market, particularly in specialized ultrafiltration applications.
Upturn SWOT Analysis
Strengths
- Proprietary ultrafiltration technology
- Focus on niche markets with specialized needs
- Potential for growth in infection control applications
- Innovative products
Weaknesses
- Limited financial resources compared to larger competitors
- Small market share in competitive dialysis market
- Dependence on specific product lines
- Sales and marketing scale is small
Opportunities
- Expanding into new geographic markets
- Developing new applications for its ultrafiltration technology
- Partnerships with larger healthcare providers
- Capitalize on recent FDA approvals
Threats
- Competition from larger, more established companies
- Changing regulations in the healthcare industry
- Economic downturn affecting healthcare spending
- Technological obsolescence
Competitors and Market Share
Key Competitors
- FMS
- BAX
- DHR
Competitive Landscape
Nephros faces stiff competition from large, established players with greater resources. Its competitive advantage is its specialized technology and focus on niche markets, but it must innovate to maintain its position.
Growth Trajectory and Initiatives
Historical Growth: The information for historical growth trends depends on the period you are analyzing which has not been provided and therefore cannot be analyzed.
Future Projections: Future projections depend on analyst estimates. Please refer to analyst reports for estimates on future growth.
Recent Initiatives: Recent strategic initiatives may include product development, expansion into new markets, or partnerships. Current details are unavailable without latest filings.
Summary
Nephros is a small player in the ultrafiltration and dialysis market, holding a niche market. They have strong proprietary ultrafiltration technology and potential for growth in infection control and biopharmaceutical applications. Key weaknesses include its small market share and dependence on key product lines. Competitors pose the biggest threat.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and financial information are estimates and may not be precise. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nephros Inc
Exchange NASDAQ | Headquaters South Orange, NJ, United States | ||
IPO Launch date 2004-09-21 | President, CEO & Director Mr. Robert Banks | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 31 | Website https://www.nephros.com |
Full time employees 31 | Website https://www.nephros.com | ||
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.